KVD824 / KalVista - LARVOL DELTA

KVD824-201: A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (clinicaltrials.gov) - P2 | N=33 | Terminated | Sponsor: KalVista Pharmaceuticals, Ltd. | N=48 ➔ 33 | Trial completion date: Jul 2023 ➔ Oct 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2023 ➔ Oct 2022; Terminated by Sponsor due to adverse events reported

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers (clinicaltrials.gov) - P1; N=108; Completed; Sponsor: KalVista Pharmaceuticals, Ltd.

Clinical • New P1 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations (clinicaltrials.gov) - P1; N=37; Completed; Sponsor: KalVista Pharmaceuticals, Ltd.

Clinical • New P1 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

KVD824-201: Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (clinicaltrials.gov) - P2; N=48; Recruiting; Sponsor: KalVista Pharmaceuticals, Ltd.

New P2 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema